🔍 In the year 2024, the landscape of clinical trials saw a significant enrollment trend across different phases. 📊 Phase III Trials 529,388 participants Showcased the highest level of engagement and interest 📊 Phase II Trials 169,108 participants Demonstrated substantial involvement in mid-stage research 📊 Phase I Trials 68,180 participants Highlighted the initial phase of testing and development These numbers underscore the critical role each phase plays in advancing medical research and development. Phase III trials, in particular, stand out for their pivotal contributions to bringing groundbreaking treatments closer to reality. As we move forward, the continued growth and participation in clinical trials will be essential in driving innovation and improving patient care. #clinicaltrials #clinicalresearch #clinicaltrialdata #clinicaltrialdatabase #clinicaldataresearch #AIinClinicalResearch #medicalresearch
ngram
Software Development
San Francisco, CA 7,359 followers
Life Sciences Data. Now Connected and Conversable.
About us
Leveraging AI to transform life sciences. We are committed to turning data into actionable insights and ensuring meaningful interactions within healthcare organizations.
- Industry
- Software Development
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
Locations
-
Primary
San Francisco, CA, US
Employees at ngram
Updates
-
This type of cancer is projected to have 310,720 new cases in 2024 👉🏽 #oncology #womenshealth
This content isn’t available here
Access this content and more in the LinkedIn app
-
#Oncology represents the largest segment in the #BioPharma industry, generating over $200 billion annually. Here's a quick peek at who's leading the pack after the first quarter of 2024 🚀 #PharmaData #BioPharmaData #BioPharmaMarket #PharmaIndustry
-
🚀 Earlier this year, we launched MedChatQA to transform how healthcare professionals (HCPs) access drug information. We’re excited to share some major milestones: 📈 400+ Downloads: MedChatQA has been downloaded over 400 times! 🏅 Setting Standards: Our dataset aims to establish a benchmark for testing large language models in delivering accurate Q&A on real-world medical topics. 🌟 Impact-Driven: We focus on enhancing information access quality and speed for HCPs, ultimately improving patient care. 📚 Comprehensive Resource: MedChatQA dataset includes ~30,000 questions covering ~1,000 FDA-approved human prescription drugs, supporting developers of Generative AI products in the medical sector. #healthcaredata #pharmadata #datasets #medicalinformation #medicalresearch
-
We've made a number of enhancements to our 🔬 clinical trials database, this week! These advancements are designed to simplify and streamline your wokflow, and also improve the depth of your searches. Take a detailed look at these updates on our blog (link in comments) 👇🏽 #clinicalresearch #clinicaltrials #medicaltrials #clinicaltrialdata #medicalresearch
-
Pharmaceutical market research is evolving rapidly with AI 🤖 at the forefront. From improving R&D 🎙 efficiency to revolutionizing drug discovery 💊 and cancer treatment, AI technologies like NLP and machine learning are transforming the industry. Dive into our blog to see how our AI-driven platform offers real-time updates and automated literature reviews, providing unparalleled insights and a competitive edge 👇 https://lnkd.in/gyp8sByp #pharma #pharmaindustry #pharmaceuticalresearch #pharmamarketresearch #marketresearch #AIinLifeSciences #pharmamarket
-
#Oncology data experts, are you keeping your 👀 on this #poll? #pharmaceuticalindustry #pharma #biopharma #biopharmaindustry #pharmamarket #pharmaindustry
This content isn’t available here
Access this content and more in the LinkedIn app
-
📈 Exciting developments in the #biopharma industry! After a slowdown in 2022 and 2023, mergers and acquisitions (M&A) activity is surging in 2024. Here are the key highlights from GlobalData's latest report: 🔄 Biopharma M&A increased by 71% year-over-year in Q1 2024. 💰 Total deal value reached $43.5 billion in Q1 2024. 🌟 Mega M&A deals are expected to positively impact the pharma industry throughout the year. 💼 Novo Holdings made the biggest deal with a $16.5 billion acquisition of Catalent to boost obesity drug manufacturing. 🔬 Gilead Sciences acquired CymaBay Therapeutics for $4.3 billion. 🧬 Antibody-drug conjugates (ADCs) are attracting high levels of investment. 🤝 Smaller acquisitions include Johnson & Johnson's $2 billion purchase of Ambrx Biopharma and AstraZeneca's $2 billion acquisition of Fusion Pharmaceuticals. 🧪 Oncology remains the leading therapeutic area for M&A, with a total deal value of $29 billion. 🚀 Immunology-focused deals saw a 314% increase in deal value compared to last year. 🔮 The report anticipates more M&A activity throughout 2024, potentially accelerating R&D and innovative drug launches. Business analysts at GlobalData Plc believe that the recent upturn in #biopharmaceutical #M&A signals a return in dealmaking confidence. 🌟 #biopharmaindustry #pharmaindustry #pharma
-
With the major public #BioPharma companies having released their first-quarter results for 2024, let's examine the world's top-selling medicines 💊 #PharmaData #BioPharmaData #BioPharmaMarket #PharmaIndustry